Archive: June 2017
Pediatric Cancer
Drug Development for Rare Cancers in Children
Lia Gore, MD
H&O How is a rare cancer defined? LG Approximately 1.6 million cases of cancer are diagnosed each year in the United States. The US Food […]
Colorectal Cancer
Locoregional Therapy for Liver Metastases in Colorectal Cancer
Andrew S. Kennedy, MD
H&O How often does colorectal cancer (CRC) metastasize to the liver? AK The exact frequency has been controversial for a long time. Current data suggest […]
Bladder Cancer
Immunotherapy in Urothelial Cancer, Part 1: T-Cell Checkpoint Inhibition in Advanced or Metastatic Disease
Steven S. Yu, MD, Tanya B. Dorff, MD, Leslie K. Ballas, MD, Sarmad Sadeghi, MD, PhD, Eila C. Skinner, MD, and David I. Quinn, MBBS (Hons), PhD, FRACP, FACP
Abstract: Cancer of the urothelium is the sixth most common cancer in the United States and is seen predominantly in men. Most cases of this […]
Kidney Cancer
Combined Blockade of Vascular Endothelial Growth Factor and Programmed Death 1 Pathways in Advanced Kidney Cancer
David J. Einstein, MD, and David F. McDermott, MD
Abstract: Targeted and immune-based therapies have improved outcomes in advanced kidney cancer, yet novel strategies are needed to extend the duration of these benefits and […]
Myeloma
Use of Genetic Markers in Multiple Myeloma
Rafael Fonseca, MD
H&O In what ways is multiple myeloma a genetically heterogeneous disease? RF In an editorial written several years ago, I referred to this disease as […]
Lung Cancer in Focus
Programmed Death Ligand 1 Testing: Is There One Best Test?
Fred R. Hirsch, MD, PhD
H&O Is programmed death ligand 1 (PD-L1) testing always done before prescribing a programmed death 1 (PD-1)/PD-L1 inhibitor in patients with non–small cell lung cancer […]
Leukemia
Counterpoints: Should Treatment for CML Continue Indefinitely?
Nicholas J. Short, MD, Elias Jabbour, MD, Gabriel Etienne, MD, PhD, and François-Xavier Mahon, MD, PhD
Since the advent of tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) has been transformed from a disease that was usually fatal into one in which […]
HCC
The BALAD-2 and GALAD Biomarker Models for Hepatocellular Carcinoma
Philip J. Johnson, MD
H&O Do biomarkers currently have a role in hepatocellular carcinoma? PJ The role of biomarkers in hepatocellular carcinoma (HCC) is controversial. For example, the best-known […]
Letter From the Editor
Letter From the Editor: In Memory of Robert L. Comis, MD
Brad S. Kahl, MD
I recently attended the Spring ECOG-ACRIN Cancer Research Group meeting. One evening I was able to spend some time at the bar with Group co-chair Bob Comis, […]